<?xml version="1.0" encoding="UTF-8"?>
<p>The treatment of multiple myeloma (MM) has advanced over the past two decades with the introduction of proteasome inhibitors and immunomodulatory drugs, leading to improved survival for patients (Kumar 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0026" ref-type="ref">2008</xref>, 
 <xref rid="bjh15394-bib-0028" ref-type="ref">2014a</xref>). Data from phase 3 randomized trials in patients with newly diagnosed MM (NDMM) or relapsed/refractory MM (RRMM) have typically demonstrated the benefit of a triplet regimen compared with a doublet regimen, particularly triplet regimens containing a proteasome inhibitor (e.g., bortezomib, carfilzomib or ixazomib) and an immunomodulatory drug (e.g., thalidomide or lenalidomide) (Cavo 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0007" ref-type="ref">2010</xref>, 
 <xref rid="bjh15394-bib-0008" ref-type="ref">2012</xref>; Garderet 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0014" ref-type="ref">2012</xref>; Rosinol 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0043" ref-type="ref">2012</xref>; Stewart 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0045" ref-type="ref">2015</xref>; Moreau 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0035" ref-type="ref">2016</xref>; Durie 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0012" ref-type="ref">2017</xref>; Kumar 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0032" ref-type="ref">2017</xref>). Additionally, early‐phase studies in NDMM patients have demonstrated favourable tolerability and efficacy with a triplet regimen comprising carfilzomib plus lenalidomide and dexamethasone (KRd) (Jakubowiak 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0022" ref-type="ref">2012</xref>; Dytfeld 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0013" ref-type="ref">2014</xref>; Korde 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0024" ref-type="ref">2015</xref>; Roussel 
 <italic>et al</italic>, 
 <xref rid="bjh15394-bib-0044" ref-type="ref">2016</xref>).
</p>
